Oncotelic Therapeutics, Inc.: Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide ...

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano, a clinical-stage nanomedicine company, today announced new data ...